These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19051610)
21. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Buzková H; Pechandová K; Slanar O; Perlík F Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358 [TBL] [Abstract][Full Text] [Related]
22. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736 [TBL] [Abstract][Full Text] [Related]
23. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Ishiguro A; Kubota T; Ishikawa H; Iga T Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890 [TBL] [Abstract][Full Text] [Related]
24. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042 [TBL] [Abstract][Full Text] [Related]
25. A rapid thin layer chromatographic procedure to identify poor and extensive oxidative drug metabolizers in man using dextromethorphan. De Zeeuw RA; Eikema D; Franke JP; Jonkman JH Pharmazie; 1992 May; 47(5):346-8. PubMed ID: 1409826 [TBL] [Abstract][Full Text] [Related]
26. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference? Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J Therapie; 2000; 55(3):349-53. PubMed ID: 10967711 [TBL] [Abstract][Full Text] [Related]
27. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy]. Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218 [TBL] [Abstract][Full Text] [Related]
28. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600 [TBL] [Abstract][Full Text] [Related]
29. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073 [TBL] [Abstract][Full Text] [Related]
30. Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico. Lares-Asseff I; Sosa-Macías M; Elizondo-Azuela G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F Proc West Pharmacol Soc; 2005; 48():102-7. PubMed ID: 16416672 [TBL] [Abstract][Full Text] [Related]
31. Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Duché JC; Quérol-Ferrer V; Barré J; Mésangeau M; Tillement JP Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):392-8. PubMed ID: 8225685 [TBL] [Abstract][Full Text] [Related]
32. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. Lutz U; Völkel W; Lutz RW; Lutz WK J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):217-25. PubMed ID: 15556536 [TBL] [Abstract][Full Text] [Related]
33. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075 [TBL] [Abstract][Full Text] [Related]
34. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. Desmeules JA; Oestreicher MK; Piguet V; Allaz AF; Dayer P J Pharmacol Exp Ther; 1999 Feb; 288(2):607-12. PubMed ID: 9918565 [TBL] [Abstract][Full Text] [Related]
35. Frequency distribution of dextromethorphan O-demethylation in a Greek population. Kimiskidis VK; Niopas I; Firinidis PD; Kanaze FI; Gabrieli C; Kazis D; Papagiannopoulos S; Kazis A Int J Clin Pharmacol Ther; 2005 Mar; 43(3):150-3. PubMed ID: 15792399 [TBL] [Abstract][Full Text] [Related]
36. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768 [TBL] [Abstract][Full Text] [Related]
37. [Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping]. Chen SQ; Cai WM; Wedlund PJ Yao Xue Xue Bao; 1997 Dec; 32(12):924-7. PubMed ID: 11596190 [TBL] [Abstract][Full Text] [Related]
38. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]. Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S Encephale; 2000; 26(1):62-7. PubMed ID: 10875063 [TBL] [Abstract][Full Text] [Related]
40. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation]. Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]